LY2886721 + Placebo

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Alzheimer's Disease

Conditions

Alzheimer's Disease

Trial Timeline

Dec 1, 2010 → Apr 1, 2011

NCT ID

NCT01227252

About LY2886721 + Placebo

LY2886721 + Placebo is a phase 1 stage product being developed by Eli Lilly for Alzheimer's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01227252. Target conditions include Alzheimer's Disease.

What happened to similar drugs?

20 of 20 similar drugs in Alzheimer's Disease were approved

Approved (20) Terminated (2) Active (0)

✅Alfoatirin® Tab. + Aripezil® Tab. + Aripezil® Tab.YuhanApproved

✅DonepezilEisaiApproved

✅DONEPEZIL HYDROCHLORIDEEisaiApproved

✅Donepezil HCLEisaiApproved

✅Donepezil HClEisaiApproved

✅Donepezil HydrochlorideEisaiApproved

✅AriceptEisaiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01807026	Phase 1	Completed	Mar 1, 2013	May 1, 2013	Alzheimer Disease
NCT01561430	Phase 1/2	Terminated	Mar 1, 2012	Aug 1, 2013	Alzheimer's Disease
NCT01534273	Phase 1	Completed	Feb 1, 2012	Jul 1, 2012	Healthy Volunteers
NCT01227252	Phase 1	Completed	Dec 1, 2010	Apr 1, 2011	Alzheimer's Disease
NCT01133405	Phase 1	Completed	Jun 1, 2010	Oct 1, 2010	Alzheimer's Disease

Competing Products

20 competing products in Alzheimer's Disease

See all competitors

Product	Company	Stage	Hype Score
LY450139 + Placebo	Eli Lilly	Phase 3	40
Solanezumab + Placebo	Eli Lilly	Phase 3	32
LY450139 dihydrate + placebo	Eli Lilly	Phase 2	35
GSK4527226	Alector	Phase 2	29
GSK4527226	Alector	Phase 2	32
AL002	Alector	Phase 2	17
Solanezumab + Placebo	Eli Lilly	Phase 3	32
simufilam	Cassava Sciences	Phase 2	17
Remternetug + Placebo	Eli Lilly	Phase 3	44
solanezumab	Eli Lilly	Phase 2	35
Gantenerumab + Gantenerumab + Gantenerumab + Placebo	Chugai Pharmaceutical	Phase 1	29
Alfoatirin® Tab. + Aripezil® Tab. + Aripezil® Tab.	Yuhan	Approved	39
FK962	Astellas Pharma	Phase 2	27
ASP0777 + Placebo	Astellas Pharma	Phase 1	29
Elenbecestat + Placebo	Eisai	Phase 3	32
Donepezil	Eisai	Approved	43
Aricept (donepezil SR 23 mg) + Aricept (donepezil IR 10 mg)	Eisai	Phase 3	40
Donepezil hydrochloride	Eisai	Phase 3	40
Donepezil Hydrochloride	Eisai	Pre-clinical	26
Lecanemab IV + Placebo + Lecanemab SC	Eisai	Phase 3	44